Role of Carma1 in Inflammatory Lung Disease
Carma1 在炎症性肺病中的作用
基本信息
- 批准号:7466234
- 负责人:
- 金额:$ 40.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-01 至 2012-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAntigensAsthmaBackcrossingsBiochemical GeneticsBiologyCell Differentiation processCell physiologyChronic DiseaseCollectionComplexDataDevelopmentDiseaseDisruptionExperimental DesignsFamilyGenerationsGenesGlucocorticoidsGoalsHealthHost DefenseImmune responseImmunosuppressive AgentsInfectionInflammationInflammatoryLungLung diseasesLymphocyteMediatingMediator of activation proteinMemoryModelingMolecularMusMutant Strains MiceMutationOutcome StudyPathogenesisPathway interactionsPharmaceutical PreparationsPhosphorylationPhosphorylation SitePhosphotransferasesPlayPneumoniaPopulationProcessProtein FingerprintsProteinsProteomicsPublic HealthReceptor SignalingRegulationResolutionRoleScaffolding ProteinSerineSignal PathwaySignal TransductionStudy SectionT memory cellT-Cell ActivationT-Cell DevelopmentT-Cell ReceptorT-LymphocyteTestingTh2 CellsTransgenic MiceTransgenic Organismsairway inflammationallergic airway inflammationantigen challengebaseimmune functionin vivoin vivo Modelinsightintermolecular interactionmouse modelnovelnovel therapeuticspromotertherapeutic targettranscription factortransmission process
项目摘要
DESCRIPTION (provided by applicant): NF-?B is a transcription factor crucial for regulating the expression of many genes involved in inflammation, and for the development of T cell-mediated inflammatory diseases such as asthma. Recent studies have demonstrated that the CARMA1-Bcl10- MALT1 signaling pathway is essential for TCR mediated NF-?B activation. Consistent with this, we have demonstrated that CARMA1 is essential for the development of allergic airway inflammation through its role in T lymphocytes. Furthermore, we have shown that CARMA1 dependent signal transmission is regulated by sequential phosphorylation by kinases. However, the exact mechanism of CARMA1 regulation in vivo remains elusive. In four interrelated aims, we will explore the regulation of CARMA1 in T cells and determine the effect of disruption of CARMA1 expression after the establishment of Th2-type pulmonary inflammation. The experimental design emphasizes the use of in vivo models of pulmonary inflammation as well as conventional approaches based on the analysis of interacting proteins using biochemical and genetic studies. The outcome of these studies will provide insight into NF-?B signaling in health and pulmonary inflammation, and may identify novel therapeutic targets. Aim 1: To characterize the role of CARMA1 in T lymphocytes during the development of allergic airway inflammation in a murine model of asthma. Aim 2: To characterize the role of CARMA1 in regulatory T cell (Treg) development and function in a murine model of asthma. Aim 3: To determine the in vivo role of serine phosphorylation of CARMA1 in lymphocyte signaling by transgenic analysis. Aim 4: To delineate novel components of signaling pathways activated by CARMA1 in T lymphocytes. PUBLIC HEALTH RELEVANCE. Asthma remains one of the most common chronic diseases in the world. Although effective therapy is achieved by the use of glucocorticoids and immunosuppressants, these drugs suppress a broad spectrum of immune function. In this proposal we investigate a protein involved in the development of asthma in a mouse model of disease. The information obtained from our proposed studies may allow us to develop more specific therapy for this disorder.
描述(由申请人提供):NF-?b对于调节许多涉及炎症基因的表达以及T细胞介导的炎症性疾病(如哮喘)的发展至关重要。最近的研究表明,CARMA1-BCL10-MALT1信号通路对于TCR介导的NF-?B激活至关重要。与此一致,我们已经证明CARMA1通过其在T淋巴细胞中的作用而对过敏性气道炎症的发展至关重要。此外,我们已经表明,CARMA1依赖性信号传递受激酶的顺序磷酸化调节。然而,体内CARMA1调节的确切机制仍然难以捉摸。在四个相互关联的目标中,我们将探索T细胞中Carma1的调节,并确定建立Th2型肺部炎症后CARMA1表达的破坏作用。实验设计强调了基于生化和遗传研究对相互作用蛋白的分析,使用肺部炎症的体内模型以及常规方法。这些研究的结果将为健康和肺部炎症中的NF-信号传导提供洞察力,并可以鉴定出新的治疗靶标。目标1:表征Carma1在哮喘的鼠模型中过敏性气道炎症过程中T淋巴细胞中的作用。目标2:表征Carma1在哮喘的鼠模型中Carma1在调节性T细胞(TREG)发育和功能中的作用。 AIM 3:通过转基因分析确定Carma1的丝氨酸磷酸化在淋巴细胞信号中的体内作用。 AIM 4:描绘由Carma1在T淋巴细胞中激活的信号通路的新成分。公共卫生相关性。哮喘仍然是世界上最常见的慢性疾病之一。尽管通过使用糖皮质激素和免疫抑制剂来实现有效的治疗,但这些药物抑制了广泛的免疫功能。在此提案中,我们研究了一种参与疾病小鼠模型中哮喘发展的蛋白质。从我们提出的研究中获得的信息可能使我们能够为这种疾病开发更具体的疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Benjamin David Medoff其他文献
Benjamin David Medoff的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Benjamin David Medoff', 18)}}的其他基金
Trained Immunity in the Airway Mucosa Differentiates Asthma from Allergy Alone
气道粘膜经过训练的免疫力可将哮喘与单纯过敏区分开来
- 批准号:
10673238 - 财政年份:2023
- 资助金额:
$ 40.86万 - 项目类别:
Targeting durotaxis in lung injury and fibrosis
靶向肺损伤和纤维化中的杜罗轴
- 批准号:
10364927 - 财政年份:2021
- 资助金额:
$ 40.86万 - 项目类别:
Targeting durotaxis in lung injury and fibrosis
靶向肺损伤和纤维化中的杜罗轴
- 批准号:
10532249 - 财政年份:2021
- 资助金额:
$ 40.86万 - 项目类别:
Targeting the ADAM10-sEphrin-B2 pathway in pulmonary fibrosis
靶向 ADAM10-sEphrin-B2 通路治疗肺纤维化
- 批准号:
10599961 - 财政年份:2019
- 资助金额:
$ 40.86万 - 项目类别:
Targeting the ADAM10-sEphrin-B2 pathway in pulmonary fibrosis
靶向 ADAM10-sEphrin-B2 通路治疗肺纤维化
- 批准号:
10372067 - 财政年份:2019
- 资助金额:
$ 40.86万 - 项目类别:
Role of Carma1 in Inflammatory Lung Disease
Carma1 在炎症性肺病中的作用
- 批准号:
7591206 - 财政年份:2008
- 资助金额:
$ 40.86万 - 项目类别:
Role of Carma1 in Inflammatory Lung Disease
Carma1 在炎症性肺病中的作用
- 批准号:
7771637 - 财政年份:2008
- 资助金额:
$ 40.86万 - 项目类别:
相似国自然基金
嗜碱性粒细胞参与抗原诱发的“特应性皮炎-哮喘”过敏进程的作用和机制研究
- 批准号:81972930
- 批准年份:2019
- 资助金额:55 万元
- 项目类别:面上项目
sPLA2-X及其信号通路在腺病毒载体携带结核抗原对支气管哮喘免疫保护中的作用及机制研究
- 批准号:81860008
- 批准年份:2018
- 资助金额:35.0 万元
- 项目类别:地区科学基金项目
IL-25作为始动因子对过敏性哮喘嗜酸粒细胞抗原递呈作用的研究
- 批准号:81870021
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
IL-35依赖的免疫调节T细胞iT(R)35对抗原特异性记忆T细胞的抑制在过敏性哮喘特异性免疫治疗中的作用和机制研究
- 批准号:81700037
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
靶向抗原特异性T细胞融合蛋白疫苗的构建及其抑制过敏性哮喘的机理研究
- 批准号:81701589
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Novel humanized mouse model of mucosal immunity
新型人源化小鼠粘膜免疫模型
- 批准号:
10591854 - 财政年份:2023
- 资助金额:
$ 40.86万 - 项目类别:
Expecting Mothers' Study of Consumption or Avoidance of Peanut and Egg (ESCAPE)
准妈妈食用或避免花生和鸡蛋的研究(ESCAPE)
- 批准号:
10733927 - 财政年份:2023
- 资助金额:
$ 40.86万 - 项目类别:
Chemotactic Cytokines Gordon Research Conference and Seminar
趋化细胞因子戈登研究会议及研讨会
- 批准号:
10468353 - 财政年份:2022
- 资助金额:
$ 40.86万 - 项目类别:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
项目 3:体外建模以确定儿童疫苗反应、呼吸道传染病和哮喘易感性机制
- 批准号:
10589826 - 财政年份:2022
- 资助金额:
$ 40.86万 - 项目类别:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
项目 3:体外建模以确定儿童疫苗反应、呼吸道传染病和哮喘易感性机制
- 批准号:
10435043 - 财政年份:2022
- 资助金额:
$ 40.86万 - 项目类别: